within Pharmacolibrary.Drugs.ATC.C;

model C01EB06
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0033333333333333335,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01EB06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fosfocreatine (also known as phosphocreatine) is a high-energy phosphate molecule used to rapidly regenerate ATP in tissues with high energy demands, such as muscle and brain. It has been investigated as a cardioprotective agent during cardiac surgery and acute myocardial infarction but is not widely approved for clinical use in most countries. Its clinical applications are limited and mainly experimental or adjunctive.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult subjects following intravenous administration in absence of published comprehensive PK profiles.</p><h4>References</h4><ol><li><p>Haapaniemi, T, et al., &amp; Larsson, J (1996). Hyperbaric oxygen reduces ischemia-induced skeletal muscle injury. <i>Plastic and reconstructive surgery</i> 97(3) 602–609. DOI:<a href=&quot;https://doi.org/10.1097/00006534-199603000-00017&quot;>10.1097/00006534-199603000-00017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8596792/&quot;>https://pubmed.ncbi.nlm.nih.gov/8596792</a></p></li><li><p>Marzo, A, et al., &amp; Croce, G (1972). [Pharmacokinetics of creatinol-o-phosphate]. <i>La Clinica terapeutica</i> 62(5) 419–430. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/5085247/&quot;>https://pubmed.ncbi.nlm.nih.gov/5085247</a></p></li><li><p>Lorenzi, E, et al., &amp; Borgoglio, R (1987). [Pharmacokinetics of phosphocreatine following intravenous administration in humans and effect on blood levels of ATP]. <i>Cardiologia (Rome, Italy)</i> 32(9) 1031–1034. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3690596/&quot;>https://pubmed.ncbi.nlm.nih.gov/3690596</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01EB06;
